CliffBio
biologic

Herzuma

trastuzumab-pkrb

Loss of exclusivity—loss of exclusivity
CompanyCelltrion →See this company's full patent-cliff portfolio

Drug detail

Brand nameHerzuma
Active ingredienttrastuzumab-pkrb
Strength150MG
Dosage formFor injection
RouteIntravenous
ModalityBiologic
FDA approvalMay 2019
Marketing statusRx

More from Celltrion

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.